2 Biotech Stocks Facing Major Catalysts in 2014
Biotechnology stocks are some of the most volatile investments around. They are hard to analyze because, unlike almost all other stocks, the fundamentals aren’t typically as important as the potential — and the potential is usually based on upcoming catalysts that the company will face. These catalysts vary, but typically include FDA decisions, drug trial results, and advisory panel decisions. The catalysts can send a particular stock soaring to new highs or back to where it began. Two biotech stocks facing major catalysts in 2014 are Lion Biotechnologies (OTC:LBIO) and Chelsea Therapeutics (NASDAQ:CHTP).
Lion Biotechnologies is a development stage biotechnology company focused on developing and commercializing adoptive cell therapy using autologous tumor infiltrating lymphocytes for the treatment of Stage IV metastatic melanoma and other cancers. Shares of Lion Biotechnologies have been on a tear since the beginning of November.
As of Friday’s closing price of $8.42, shares have soared by nearly 80 percent since November 1 on expectations that the company’s technology and catalysts in 2014 will turn Lion Biotechnologies into one of the premier biotechnology companies in the world.